Oryzon Genomics S.A. (BME:ORY)
Spain
· Delayed Price · Currency is EUR 2.630
+0.005 (0.19%)
Aug 15, 2025, 5:35 PM CET
Oryzon Genomics Revenue
Oryzon Genomics had revenue of 4.22M EUR in the quarter ending June 30, 2025, with 2.73% growth. This brings the company's revenue in the last twelve months to 7.47M, down -30.93% year-over-year. In the year 2024, Oryzon Genomics had annual revenue of 7.36M, down -48.15%.
Revenue (ttm)
7.47M
Revenue Growth
-30.93%
P/S Ratio
27.29
Revenue / Employee
158.96K
Employees
47
Market Cap
203.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.36M | -6.83M | -48.15% |
| Dec 31, 2023 | 14.19M | -1.51M | -9.60% |
| Dec 31, 2022 | 15.70M | 5.08M | 47.88% |
| Dec 31, 2021 | 10.62M | 1.09M | 11.49% |
| Dec 31, 2020 | 9.52M | -756.51K | -7.36% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.45B |
| Laboratorios Farmaceuticos Rovi | 749.00M |
| Almirall | 1.05B |
| Pharma Mar | 189.27M |
| Faes Farma | 543.77M |
| Clínica Baviera | 288.92M |
| Laboratorio Reig Jofre | 336.02M |
| Atrys Health | 218.10M |
Oryzon Genomics News
- 17 days ago - ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025 - Benzinga
- 3 months ago - Oryzon Genomics S.A. GAAP EPS of -$0.03 - Seeking Alpha
- 6 months ago - Oryzon Genomics S.A. GAAP EPS of -$0.02 - Seeking Alpha
- 7 months ago - ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting - Benzinga